Rinvoq

Rinvoq (upadacitinib) is a prescription medication used to treat Rheumatoid arthritis, psoriatic arthritis, eczema. Rinvoq is an oral once-daily tablet advertised in Canada for adults with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and moderate-to-severe atopic dermatitis.

Rinvoq inhibits JAK1 (Janus kinase 1), an enzyme involved in the inflammatory signaling pathway. By blocking JAK1, it reduces the inflammatory signals driving rheumatoid arthritis and eczema.

Commonly reported side effects of Rinvoq include Serious infections, Blood clots, Cardiovascular events, Cancer risk, Liver problems, and Decreased blood counts. This is not a complete list — tell your doctor or pharmacist about any side effects you experience.

Yes. Rinvoq carries an FDA Boxed Warning — the agency's most serious safety warning. Read the full prescribing information and talk to your doctor about the risks before starting or changing treatment.

The active ingredient in Rinvoq is upadacitinib, which belongs to a class of medicines known as JAK Inhibitor.

Rinvoq is manufactured by AbbVie. It was first approved in 2019.

You may be able to lower the cost of Rinvoq by using a free pharmacy discount card or by comparing prices across pharmacies before you fill your prescription. Savings vary by pharmacy and location.